Insights

Innovative Therapeutic Approach AFFiRiS AG utilizes its proprietary Specific Active ImmunoTherapy (SAIT) technology to develop immunotherapies targeting neurodegenerative diseases, presenting opportunities to collaborate on novel vaccine platforms and immune-modulating solutions for related chronic conditions.

Expanding Clinical Pipeline With ongoing clinical trials in Parkinson’s disease, MSA, DLB, and Huntington's disease, AFFiRiS offers potential partnership prospects in diagnostics, supportive therapies, and device integration to complement their immunotherapy products.

Recent Partnerships Collaborations like the one with Frontier Biotech highlight AFFiRiS’s openness to licensing and joint development opportunities, suggesting a strategic avenue for joint ventures, technology licensing, or distribution partnerships in precision immunotherapy.

Focus on Unmet Needs Targeting diseases with limited current treatment options, such as neurodegenerative disorders, positions AFFiRiS as a key player for organizations looking to expand into highly underserved markets with high growth potential.

Growing Funding & Engagement Despite a modest revenue profile, AFFiRiS’s $11 million funding and recent executive appointments reveal a company in growth mode, offering opportunities for investors or suppliers to engage with a biotech innovator focused on groundbreaking therapies.

Similar companies to AFFiRiS AG

AFFiRiS AG Tech Stack

AFFiRiS AG uses 8 technology products and services including Cookie Notice, oEmbed, jQuery UI, and more. Explore AFFiRiS AG's tech stack below.

  • Cookie Notice
    Cookie Compliance
  • oEmbed
    Dev Tools
  • jQuery UI
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • WPBakery
    Page Builders
  • Yoast SEO
    Search Engines
  • Apache HTTP Server
    Web Servers

AFFiRiS AG's Email Address Formats

AFFiRiS AG uses at least 1 format(s):
AFFiRiS AG Email FormatsExamplePercentage
First.Last@affiris.comJohn.Doe@affiris.com
50%
First.Last@affiris.comJohn.Doe@affiris.com
50%

Frequently Asked Questions

Where is AFFiRiS AG's headquarters located?

Minus sign iconPlus sign icon
AFFiRiS AG's main headquarters is located at 22 Karl-farkas-gasse Wien, Hietzing, Wien 1030 Austria. The company has employees across 2 continents, including EuropeNorth America.

What is AFFiRiS AG's phone number?

Minus sign iconPlus sign icon
You can contact AFFiRiS AG's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AFFiRiS AG's official website and social media links?

Minus sign iconPlus sign icon
AFFiRiS AG's official website is affiris.com and has social profiles on LinkedInCrunchbase.

What is AFFiRiS AG's SIC code NAICS code?

Minus sign iconPlus sign icon
AFFiRiS AG's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AFFiRiS AG have currently?

Minus sign iconPlus sign icon
As of February 2026, AFFiRiS AG has approximately 3 employees across 2 continents, including EuropeNorth America. Key team members include Clinical Project Manager: B. A.Personal Assistant: K. N.: A. K.. Explore AFFiRiS AG's employee directory with LeadIQ.

What industry does AFFiRiS AG belong to?

Minus sign iconPlus sign icon
AFFiRiS AG operates in the Biotechnology Research industry.

What technology does AFFiRiS AG use?

Minus sign iconPlus sign icon
AFFiRiS AG's tech stack includes Cookie NoticeoEmbedjQuery UIModernizrSwiperWPBakeryYoast SEOApache HTTP Server.

What is AFFiRiS AG's email format?

Minus sign iconPlus sign icon
AFFiRiS AG's email format typically follows the pattern of First.Last@affiris.com. Find more AFFiRiS AG email formats with LeadIQ.

How much funding has AFFiRiS AG raised to date?

Minus sign iconPlus sign icon
As of February 2026, AFFiRiS AG has raised $11M in funding. The last funding round occurred on Apr 25, 2017 for $11M.

When was AFFiRiS AG founded?

Minus sign iconPlus sign icon
AFFiRiS AG was founded in 2003.

AFFiRiS AG

Biotechnology ResearchWien, Austria2-10 Employees

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

WE FOCUS ON UNMET MEDICAL NEEDS IN CHRONIC DISEASES
Currently available treatments for many neurodegenerative diseases aim to manage symptoms, and do not stop disease progression. As a result, neurodegenerative diseases often lead to a reduced quality of life. Better treatments for these diseases are needed to give patients healthier, happier, and longer lives. We aim to develop therapeutic and preventative treatments that address the root causes of neurodegenerative diseases: an ethos inspired by the impact of vaccines on health and society worldwide.

OUR APPROACH
Our novel approach, Specific Active ImmunoTherapy (SAIT), stimulates the body’s own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT was developed using our AFFITOME technology, which allows for optimization of immune responses against pathogenic forms of proteins, and it may permit targeting of multiple pathogenic proteins in one disease setting. SAIT is designed to induce a long-lasting immune response, which we anticipate will translate into effective quarterly/twice-yearly dosing.

OUR PIPELINE
We have a broad portfolio of immunotherapy candidates, which are currently in clinical trials or preclinical development for chronic diseases, including Parkinson’s Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease.

OUR TEAM
We are a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. Our exciting work spans early discovery, preclinical advancement of SAIT and monoclonal antibody drug candidates, and translation of science into clinical development.

Please follow us on LinkedIn and visit www.affiris.com.

Section iconCompany Overview

Headquarters
22 Karl-farkas-gasse Wien, Hietzing, Wien 1030 Austria
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2003
Employees
2-10

Section iconFunding & Financials

  • $11M

    AFFiRiS AG has raised a total of $11M of funding over 4 rounds. Their latest funding round was raised on Apr 25, 2017 in the amount of $11M.

  • $1M

    AFFiRiS AG's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $11M

    AFFiRiS AG has raised a total of $11M of funding over 4 rounds. Their latest funding round was raised on Apr 25, 2017 in the amount of $11M.

  • $1M

    AFFiRiS AG's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.